---
title: "This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289201814.md"
description: "Wall Street analysts upgraded five stocks on Tuesday. UBS upgraded Arthur J. Gallagher (AJG) to Buy with a $250 target. Sidoti & Co. upgraded Brady Corp (BRC) to Buy with a $103 target. GLJ Research upgraded Cleveland-Cliffs (CLF) to Hold with a $15.01 target. JP Morgan upgraded PAR Technology (PAR) to Neutral with a $16 target. Barclays upgraded West Pharmaceutical Services (WST) to Overweight with a $400 target."
datetime: "2026-06-09T13:43:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289201814.md)
  - [en](https://longbridge.com/en/news/289201814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289201814.md)
---

# This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   UBS analyst Weston Bloomer upgraded **Arthur J. Gallagher & Co.** (NYSE:AJG) from Neutral to Buy and lowers the price target from $283 to $250. Arthur J. Gallagher shares closed at $212.52 on Monday. See how other analysts view this stock.
-   Sidoti & Co. analyst Steve Ferazani upgraded **Brady Corp** (NYSE:BRC) from Neutral to Buy and announced a $103 price target. Brady shares closed at $75.28 on Monday. See how other analysts view this stock.
-   GLJ Research analyst Gordon L. Johnson upgraded **Cleveland-Cliffs Inc** (NYSE:CLF) from Sell to Hold and raised the price target from $9.03 to $15.01. Cleveland-Cliffs shares closed at $12.68 on Monday. See how other analysts view this stock.
-   JP Morgan analyst Ella Smith upgraded **PAR Technology Corporation** (NYSE:PAR) from Underweight to Neutral and raised the price target from $12 to $16. PAR Technology shares closed at $13.28 on Monday. See how other analysts view this stock.
-   Barclays analyst Luke Sergott upgraded **West Pharmaceutical Services, Inc**. (NYSE:WST) from Equal-Weight to Overweight and raised the price target from $310 to $400. West Pharmaceutical shares closed at $319.75 on Monday. See how other analysts view this stock.

Considering buying BRC stock? Here’s what analysts think:

_Photo via Shutterstock_

### Related Stocks

- [WST.US](https://longbridge.com/en/quote/WST.US.md)
- [CLF.US](https://longbridge.com/en/quote/CLF.US.md)
- [PAR.US](https://longbridge.com/en/quote/PAR.US.md)
- [BRC.US](https://longbridge.com/en/quote/BRC.US.md)
- [AJG.US](https://longbridge.com/en/quote/AJG.US.md)

## Related News & Research

- [A Look At West Pharmaceutical Services (WST) Valuation After Recent Share Price Consolidation](https://longbridge.com/en/news/288933254.md)
- [West Pharmaceutical Services' (WST) "Overweight" Rating Reiterated at Stephens](https://longbridge.com/en/news/288428697.md)
- [This Analyst Just Upgraded Chipotle Stock. Here's Why.](https://longbridge.com/en/news/289079873.md)
- [Reinhart Partners LLC. Has $47.52 Million Position in PAR Technology Corporation $PAR](https://longbridge.com/en/news/288562978.md)
- [Why Are Analysts Bullish on Broadcom Stock (AVGO) Despite Today's Fall?](https://longbridge.com/en/news/288739861.md)